ARDELYX INC (ARDX) Stock Fundamental Analysis

NASDAQ:ARDX • US0396971071

6.525 USD
-0.1 (-1.58%)
Last: Feb 27, 2026, 11:35 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ARDX. ARDX was compared to 521 industry peers in the Biotechnology industry. ARDX has a bad profitability rating. Also its financial health evaluation is rather negative. ARDX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ARDX had negative earnings in the past year.
  • In the past year ARDX has reported a negative cash flow from operations.
  • In the past 5 years ARDX always reported negative net income.
  • ARDX had a negative operating cash flow in each of the past 5 years.
ARDX Yearly Net Income VS EBIT VS OCF VS FCFARDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -12.28%, ARDX belongs to the top of the industry, outperforming 82.53% of the companies in the same industry.
  • ARDX has a better Return On Equity (-36.90%) than 71.59% of its industry peers.
Industry RankSector Rank
ROA -12.28%
ROE -36.9%
ROIC N/A
ROA(3y)-14.49%
ROA(5y)-36.87%
ROE(3y)-33.03%
ROE(5y)-71.79%
ROIC(3y)N/A
ROIC(5y)N/A
ARDX Yearly ROA, ROE, ROICARDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Gross Margin of ARDX (90.29%) is better than 92.51% of its industry peers.
  • ARDX's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ARDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y-1.65%
ARDX Yearly Profit, Operating, Gross MarginsARDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ARDX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ARDX has been increased compared to 5 years ago.
  • Compared to 1 year ago, ARDX has a worse debt to assets ratio.
ARDX Yearly Shares OutstandingARDX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ARDX Yearly Total Debt VS Total AssetsARDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of 1.49, we must say that ARDX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of ARDX (1.49) is better than 64.30% of its industry peers.
  • A Debt/Equity ratio of 1.21 is on the high side and indicates that ARDX has dependencies on debt financing.
  • ARDX's Debt to Equity ratio of 1.21 is on the low side compared to the rest of the industry. ARDX is outperformed by 76.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Altman-Z 1.49
ROIC/WACCN/A
WACC8.6%
ARDX Yearly LT Debt VS Equity VS FCFARDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • ARDX has a Current Ratio of 4.31. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
  • ARDX's Current ratio of 4.31 is in line compared to the rest of the industry. ARDX outperforms 50.86% of its industry peers.
  • A Quick Ratio of 4.11 indicates that ARDX has no problem at all paying its short term obligations.
  • The Quick ratio of ARDX (4.11) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.31
Quick Ratio 4.11
ARDX Yearly Current Assets VS Current LiabilitesARDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • ARDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -53.37%.
  • The Revenue has grown by 22.09% in the past year. This is a very strong growth!
  • ARDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 121.91% yearly.
EPS 1Y (TTM)-53.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)22.09%
Revenue growth 3Y98.4%
Revenue growth 5Y121.91%
Sales Q2Q%7.82%

3.2 Future

  • ARDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 60.74% yearly.
  • Based on estimates for the next years, ARDX will show a very strong growth in Revenue. The Revenue will grow by 27.17% on average per year.
EPS Next Y157.24%
EPS Next 2Y120.07%
EPS Next 3Y74.4%
EPS Next 5Y60.74%
Revenue Next Year35.32%
Revenue Next 2Y34.72%
Revenue Next 3Y24.52%
Revenue Next 5Y27.17%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARDX Yearly Revenue VS EstimatesARDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
ARDX Yearly EPS VS EstimatesARDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ARDX. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 45.60, ARDX can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ARDX indicates a rather cheap valuation: ARDX is cheaper than 90.21% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 28.13. ARDX is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 45.6
ARDX Price Earnings VS Forward Price EarningsARDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARDX Per share dataARDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • ARDX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ARDX's earnings are expected to grow with 74.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y120.07%
EPS Next 3Y74.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ARDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARDELYX INC

NASDAQ:ARDX (2/27/2026, 11:35:42 AM)

6.525

-0.1 (-1.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)04-29
Inst Owners67.27%
Inst Owner Change13.57%
Ins Owners2.36%
Ins Owner Change4.38%
Market Cap1.59B
Revenue(TTM)407.32M
Net Income(TTM)-61.60M
Analysts90
Price Target16.2 (148.28%)
Short Float %7.93%
Short Ratio4.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0%
Min EPS beat(2)-100%
Max EPS beat(2)100%
EPS beat(4)2
Avg EPS beat(4)-1.35%
Min EPS beat(4)-100%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)59.25%
EPS beat(12)8
Avg EPS beat(12)48.51%
EPS beat(16)12
Avg EPS beat(16)412.07%
Revenue beat(2)2
Avg Revenue beat(2)5.23%
Min Revenue beat(2)3.91%
Max Revenue beat(2)6.56%
Revenue beat(4)3
Avg Revenue beat(4)5.19%
Min Revenue beat(4)-7.8%
Max Revenue beat(4)18.08%
Revenue beat(8)7
Avg Revenue beat(8)11.24%
Revenue beat(12)10
Avg Revenue beat(12)23.49%
Revenue beat(16)13
Avg Revenue beat(16)23.73%
PT rev (1m)9.3%
PT rev (3m)22.08%
EPS NQ rev (1m)-19.18%
EPS NQ rev (3m)-30.2%
EPS NY rev (1m)-1.65%
EPS NY rev (3m)22.03%
Revenue NQ rev (1m)-0.58%
Revenue NQ rev (3m)-0.08%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)2.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 45.6
P/S 3.89
P/FCF N/A
P/OCF N/A
P/B 9.5
P/tB 9.5
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)0.14
Fwd EY2.19%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS1.68
BVpS0.69
TBVpS0.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12.28%
ROE -36.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.29%
FCFM N/A
ROA(3y)-14.49%
ROA(5y)-36.87%
ROE(3y)-33.03%
ROE(5y)-71.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.66%
GM growth 5Y-1.65%
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.77%
Cap/Sales 0.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.31
Quick Ratio 4.11
Altman-Z 1.49
F-Score3
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)41.47%
Cap/Depr(5y)51.91%
Cap/Sales(3y)0.32%
Cap/Sales(5y)3.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y157.24%
EPS Next 2Y120.07%
EPS Next 3Y74.4%
EPS Next 5Y60.74%
Revenue 1Y (TTM)22.09%
Revenue growth 3Y98.4%
Revenue growth 5Y121.91%
Sales Q2Q%7.82%
Revenue Next Year35.32%
Revenue Next 2Y34.72%
Revenue Next 3Y24.52%
Revenue Next 5Y27.17%
EBIT growth 1Y-44.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year223.08%
EBIT Next 3Y125.81%
EBIT Next 5Y82.96%
FCF growth 1Y4.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.19%
OCF growth 3YN/A
OCF growth 5YN/A

ARDELYX INC / ARDX FAQ

What is the ChartMill fundamental rating of ARDELYX INC (ARDX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ARDX.


Can you provide the valuation status for ARDELYX INC?

ChartMill assigns a valuation rating of 3 / 10 to ARDELYX INC (ARDX). This can be considered as Overvalued.


How profitable is ARDELYX INC (ARDX) stock?

ARDELYX INC (ARDX) has a profitability rating of 2 / 10.


Can you provide the financial health for ARDX stock?

The financial health rating of ARDELYX INC (ARDX) is 3 / 10.